Amyloid beta-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation.
The neuropathological hallmarks of Alzheimer's disease (AD) are amyloid-containing plaques and neurofibrillary tangles. The main constituent of senile plaques is amyloid beta-peptide (A beta) and in recent years, pathogenic mutations in the amyloid precursor protein (APP) gene have been discovered in some AD families. The APP670/671 mutation, found in a Swedish AD family, has revealed over-production of A beta as one pathogenic mechanism for the development of AD. In the present study we have used an immunoassay to measure A beta levels in cerebrospinal fluid (CSF) from APP670/671 mutation-carriers and non-carriers. A correlation was seen between decrease in A beta levels and duration of disease although no difference was found in levels of A beta between the groups (14.5 +/- 3.3 ng/ml versus 14.9 +/- 2.3 ng/ml).
Lannfelt
L
L
Karolinska Institute, Department of Clinical Neuroscience and Family Medicine, Huddinge University Hospital, Sweden.
Basun
H
H
Vigo-Pelfrey
C
C
Wahlund
L O
LO
Winblad
B
B
Lieberburg
I
I
Schenk
D
D
D000328:Adult; D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000235:genetics*; D016564:Amyloid beta-Protein Precursor / Q000134:cerebrospinal fluid*; D005190:Family; D005838:Genotype; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D013548:Sweden; D013997:Time Factors
D016564:Amyloid beta-Protein Precursor